Lipocine Inc. — Q1 2015 Form 10-Q
Business context and reporting period. This unaudited quarterly report covers the three months ended March 31, 2015. Lipocine is a clinical-stage specialty pharmaceutical company developing oral drug-delivery products, principally for men’s and women’s health. It had no product-sales revenue and remained dependent on financing and potential licensing or collaboration proceeds.
Financial results and liquidity
| Metric | Q1 2015 | Q1 2014 or prior period |
|---|---|---|
| Revenue | No revenue reported for the quarter | No product-sales revenue; comparative quarterly revenue value is not stated in the provided filing text |
| Research and development expense | $1.92 million | $3.37 million |
| General and administrative expense | $1.06 million | $1.92 million |
| Operating loss | $2.97 million | $5.29 million |
| Net loss / loss per share | $2.96 million / $0.23 | $5.27 million / $0.41 |
| Cash used in operating activities | $3.03 million | $3.22 million |
| Cash and cash equivalents | $24.76 million | $27.67 million at December 31, 2014 |
| Total current assets / current liabilities | $24.95 million / $1.34 million | $27.90 million / $1.63 million at December 31, 2014 |
| Debt | No debt reported |
There were no product revenues, so revenue-based margins are not meaningful. Accumulated deficit was $71.2 million and stockholders’ equity was $23.7 million at quarter-end. Cash declined by $2.90 million during the quarter; financing included $137,000 from option exercises. The company reported no off-balance-sheet arrangements.
Changes versus the prior comparable period
- Net loss narrowed by $2.31 million year over year. R&D expense fell $1.45 million, primarily because of lower clinical research and contract manufacturing costs and lower personnel costs.
- G&A expense fell $868,000, primarily because 2014 included accelerated equity-compensation expense for retiring directors; lower legal and accounting fees also contributed.
- Operating cash use improved by approximately $192,000. Lower net loss was partly offset by lower stock-based compensation and changes in working capital.
- Cash was $17.0 million lower than at March 31, 2014, when the company reported $41.77 million.
Outlook, development programs, and risks
- LPCN 1021: The company reported that its pivotal Phase 3 SOAR trial met the primary efficacy guideline: 88% of the efficacy population achieved average testosterone levels in the normal range, with an 82% lower confidence bound. The 52-week trial’s safety component finished in late April 2015; full safety results were still under review. Management expected top-line safety results in Q2 2015 and an NDA filing in the second half of 2015, subject to satisfactory safety results and the required food-effect study.
- Other candidates: LPCN 1111 had completed a Phase 2a study; management expected a Phase 2b study to begin in Q4 2015 or Q1 2016. LPCN 1107 had completed Phase 1 proof-of-concept studies; the company planned to discuss its development path with the FDA in Q2 2015.
- Spending and funding: Management expected continued significant expenses and operating losses. It estimated approximately $7.0 million in additional LPCN 1021 R&D costs to complete Phase 3, other pharmacokinetic studies, and, if appropriate, file an NDA. It said existing resources plus the subsequent offering proceeds were expected to fund projected requirements for the next 12 months, while additional capital would be needed at some point. There was no credit facility or committed capital source.
- Subsequent offering: On April 29, 2015, after quarter-end, Lipocine sold 5,347,500 shares for approximately $34.8 million gross proceeds and reported approximately $32.5 million net proceeds.
- Key risks: Regulatory approval and commercialization remain uncertain. The LPCN 1021 food-effect study, final Phase 3 safety results, possible FDA requirements, and changing testosterone-therapy labeling could delay or limit approval or market potential. The filing also highlights cardiovascular and other perceived TRT safety risks, competition, manufacturing scale-up, and the need for future financing.
- Commitments and other items: Remaining minimum operating-lease payments were approximately $864,000 through 2018. Potential perpetual royalties to Abbott could apply to future net sales if specified formulations or data are used. Spriaso, a related party, may owe Lipocine royalties under an intellectual-property arrangement; Lipocine also agreed to provide certain services at $230 per hour for six months from January 23, 2015. The filing reported no material legal proceedings.
Important facts for investors to verify
- Whether final LPCN 1021 safety results supported the planned NDA timeline, and whether the food-effect study or FDA review required further work.
- The actual timing, acceptance, and review outcome of any LPCN 1021 NDA, including applicable TRT labeling and cardiovascular-study requirements.
- Whether the post-quarter offering’s net proceeds and the company’s subsequent cash use support the stated runway; management cautioned that estimates depend on assumptions and costs could arise sooner.
- The development path, costs, and clinical progress for LPCN 1111 and LPCN 1107, as well as LPCN 1021 manufacturing readiness and commercial-scale supply.
- Potential effects of competition, TRT safety concerns, Abbott royalty obligations, and the related-party Spriaso arrangements.